Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.30 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.30 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.30 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.30 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25754339 | 0.95 | EPHX2 (0.34) | KDM4ELMNAEPHX2CYP1A2CYP3A4 | |
| SCHEMBL25754334 | 0.89 | KDM4E (0.34) | KDM4ELMNAEPHX2MEN1KMT2A | |
| SCHEMBL25754325 | 0.81 | MAOA (0.34) | MEN1KMT2A | |
| SCHEMBL25754338 | 0.80 | CYP1A2 (0.34) | KDM4ELMNAEPHX2CYP1A2CYP3A4 | |
| SCHEMBL25754341 | 0.79 | KDM4E (0.42) | KDM4EMEN1KMT2A | |
| SCHEMBL2607368 | 0.76 | KDM4E (0.40) | KDM4ELMNAEPHX2CYP1A2CYP3A4 | |
| SCHEMBL25754330 | 0.74 | MAOA (0.34) | KDM4E | |
| SCHEMBL25754706 | 0.74 | — | — | |
| SCHEMBL25160320 | 0.71 | KDM4E (0.38) | KDM4ELMNAEPHX2CYP1A2CYP3A4 | |
| SCHEMBL15313096 | 0.71 | CYP2D6 (0.44) | KDM4ELMNAEPHX2CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230210999-A1 | TARGETED PROTEASE DEGRADATION (TED) PLATFORM | EUBULUS BIOTHERAPEUTICS (HONG KONG) LIMITED (HK) | 2023-07-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230210999-A1 | TARGETED PROTEASE DEGRADATION (TED) PLATFORM | UCHL3, UBE2L3, ADAM33 | KDM4E 2658/4885LMNA 1517/4885EPHX2 2419/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.